Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Collaborator: National Eye Institute (NEI)
• Treatments: Bevacizumab; Ranibizumab

Criteria

Inclusion Criteria:

• Active, subfoveal choroidal neovascularization (CNV)

• Fibrosis < 50% of total lesion area

• Visual acuity (VA) 20/25-20/320

• Age ≥ 50 yrs

• At least 1 drusen (>63μ) in either eye or late AMD in fellow eye

Exclusion Criteria:

• Previous treatment for CNV in study eye

• Other progressive retinal disease likely to compromise VA

• Contraindications to injections with Lucentis or Avastin